Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Princy Khurana
Institution:
Aimmune Therapeutics (United Kingdom)
Observed institutions:
University of Oxford,
Aimmune Therapeutics (United Kingdom)
OpenAlex ID:
A5055347652
Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy
2021
·
Mukesh Gangar
, Sandeep Goyal
, et al.
·
Bioorganic Chemistry
·
32
Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague–Dawley Rats
2019
·
Princy Khurana
, Tulasi Yadati
, et al.
·
Biomolecules
·
31
PDF
Inhibition of Extracellular Cathepsin D Reduces Hepatic Lipid Accumulation and Leads to Mild Changes in Inflammationin NASH Mice
2021
·
Tulasi Yadati
, Tom Houben
, et al.
·
Frontiers in Immunology
·
27
PDF
AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model
2022
·
Avijit Goswami
, Barnali Deb
, et al.
·
Molecules
·
25
PDF
Small molecule innate immune modulators in cancer therapy
2024
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Frontiers in Immunology
·
12
PDF
Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D
2020
·
Sandeep Goyal
, Ketul V. Patel
, et al.
·
Bioorganic & Medicinal Chemistry
·
8
AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
2023
·
Aditya Kulkarni
, Avijit Goswami
, et al.
·
Research Square
·
7
PDF
1334 AVA-ADR-001 supresses tumor growth and induces anti-tumor immunity by selectively inhibiting ADAR1 p150
2022
·
Arun B Papaiah
, Avijit Goswami
, et al.
·
Journal for ImmunoTherapy of Cancer
·
7
PDF
Abstract 4484: Discovery of a potential first-in-class Za targeted small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy
2024
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Cancer Research
·
6
1041 Discovery of a potential first-in-class small molecule inhibitor of ADAR1 p150 which demonstrates strong anti-tumor efficacy in B16F10 syngeneic melanoma model
2023
·
Avijit Goswami
, Barnali Deb
, et al.
·
Journal for ImmunoTherapy of Cancer
·
3
PDF
Abstract 3244: AVA-NP-695, a potent and selective ENPP1 inhibitor, abrogates tumor metastasis in 4T1 syngeneic tumor model and demonstrates strong tumor regression when combined with radiation
2023
·
Aditya Kulkarni
, Avijit Goswami
, et al.
·
Cancer Research
·
3
Abstract 6898: Identification of a novel first-in-class inhibitor targeting the ADAR1 p150 isoform demonstrates robust anti-tumor efficacy in a syngeneic mouse model
2025
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Cancer Research
·
2
740 Discovery of a potential first-in-class inhibitor targeting ADAR1 p150 isoform with strong anti-tumor efficacy in syngeneic melanoma mouse model
2024
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
864 AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation
2023
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 3095: Development of a novel ADAR1 inhibitor as a potent immunomodulator for the treatment of solid tumors
2023
·
Aditya Kulkarni
, Avijit Goswami
, et al.
·
Cancer Research
·
1
1335 AVA-NP-695 potently and selectively inhibits ENPP1 to activate STING pathway and abrogate tumor metastasis in 4T1 breast cancer syngeneic mouse model
2022
·
Aditya Kulkarni
, Avijit Goswami
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
Abstract 1559: First-in-class Zα-domain-targeted ADAR1 p150 inhibitor demonstrates potent antitumor efficacy in high IFN syngeneic melanoma
2026
·
Aditya Kulkarni
, Avijit Goswami
, et al.
·
Cancer Research
Abstract 7877: Combination of AVA-NP-695 and DDRi demonstrates strong synergy resulting in potent anti-tumor activity in rare pediatric cancers
2026
·
Aditya Kulkarni
, Borja Ruiz-Fernandez de Cordoba
, et al.
·
Cancer Research
Abstract 5808: Development of a first-in-class ENPP3-targeted radioligand for liver and renal cancer imaging
2026
·
Aditya Kulkarni
, Sandeep Goyal
, et al.
·
Cancer Research
624 AVA-NP-695 demonstrates strong anti-cancer activity in ICB-refractory & rare cancers
2025
·
Borja Ruiz Fernandez de Cordoba
, Avijit Goswami
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
1179 Discovery of a first-in-class ADAR1 p150 inhibitor targeting the Zα-domain with potent anti-tumor efficacy in syngeneic mouse models
2025
·
Avijit Goswami
, Sandeep Goyal
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Abstract 652: Exploring the therapeutic benefit of AVA-NP-695 with combination modalities in ICB refractory and rare cancers
2025
·
Borja Ruiz-Fernandez de Cordoba
, Avijit Goswami
, et al.
·
Cancer Research
809 Exploring the therapeutic benefit of AVA-NP-695 (ENPP1 inhibitor) and DNA damage inhibition to activation of the immune system in metastatic osteosarcoma
2024
·
Borja Ruiz Fernandez de Cordoba
, Avijit Goswami
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
23
Citation count:
168
H-index:
7
I10-index:
5
Year
Topic
Type